CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 37 enrolled
Drug / intervention
Forearm immobilizationbehavioral
Likely dose
Not stated in record
Key inclusion· 2
  • ✓Age 18-40 years
  • ✓Body mass index between 18 and 27
Key exclusion· 16
  • ✕Any diagnosed metabolic impairment including type 1 or 2 diabetes
  • ✕Any diagnosed cardiovascular disease
  • ✕Hypertension (≥140 mmHg systolic and/or ≥90 mmHg diastolic)
  • ✕Chronic use of prescribed or over-the-counter medications (excluding oral contraceptives and contraceptive devices)

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03866512
NCT03866512N/ACompleted
CompareCT.gov

The Impact of Acipimox and Salbutamol Supplementation on the Development of Insulin Resistance and Anabolic Resistance During Forearm Immobilization in Healthy, Young Volunteers

University of Exeter·interventional·Posted Mar 7, 2019·Updated Jun 21, 2024

In Brief

A clinical study evaluating Forearm immobilization for Healthy. Completed, enrolled 37 participants across 1 site.

Detailed Summary

The present study will investigate the impact of altered substrate availability on muscle atrophy, insulin sensitivity and muscle protein synthesis following short-term forearm immobilization

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited Kingdom
CollaboratorsWellcome Trust

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedMar 7, 2019
Enrollment StartMay 10, 2019
Primary CompletionJul 1, 2021
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 7.3 years ago

Interventions

Forearm immobilizationbehavioral

Two days of forearm immobilization